We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Pargluva Poses 'Excess' Safety Risks, JAMA Study Says
Pargluva Poses 'Excess' Safety Risks, JAMA Study Says
October 20, 2005
If approved by the FDA, Merck and Bristol-Myers Squibb’s (BMS) highly anticipated diabetes treatment Pargluva would “constitute an unacceptable patient hazard,” according to an independent clinical analysis that shows the drug poses significant safety risks.